2 results
Approved WMOPending
The objective of this phase-3 randomized study, with a double-blind treatment period of 8 weeksduration is to evaluate the efficacy and safety of the fixed dose combinations of TAK-491 pluschlorthalidone (40/12.5 mg and 40/25 mg) in subjects with…
Approved WMOCompleted
Primary objectiveTo determine whether the clinical response after 10-day oral administration of cadazolid is non-inferior to oral vancomycin in subjects with CDAD.Secondary objectivesTo determine whether oral administration of cadazolid for 10 days…